Equities research analysts predict that Eli Lilly and Company (NYSE:LLY) will post sales of $5.96 billion for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Eli Lilly and’s earnings, with estimates ranging from $5.89 billion to $6.04 billion. Eli Lilly and posted sales of $5.76 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 3.5%. The firm is scheduled to announce its next quarterly earnings results on Tuesday, January 30th.

On average, analysts expect that Eli Lilly and will report full year sales of $5.96 billion for the current year, with estimates ranging from $22.60 billion to $22.71 billion. For the next year, analysts anticipate that the business will post sales of $23.19 billion per share, with estimates ranging from $23.05 billion to $23.32 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Eli Lilly and.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The business had revenue of $5.66 billion for the quarter, compared to the consensus estimate of $5.52 billion. During the same period last year, the business posted $0.88 EPS. The business’s revenue was up 9.0% compared to the same quarter last year.

A number of research analysts have recently issued reports on the company. BMO Capital Markets reiterated a “sell” rating and issued a $71.00 price target on shares of Eli Lilly and in a report on Thursday, September 28th. Credit Suisse Group restated a “hold” rating on shares of Eli Lilly and in a research note on Wednesday, December 13th. Cowen restated a “buy” rating and set a $95.00 target price on shares of Eli Lilly and in a research note on Wednesday, October 4th. Jefferies Group restated a “buy” rating and set a $89.00 target price (down from $94.00) on shares of Eli Lilly and in a research note on Thursday, August 24th. Finally, BidaskClub downgraded Eli Lilly and from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $90.25.

Shares of Eli Lilly and (NYSE:LLY) traded down $0.46 during trading hours on Tuesday, hitting $86.08. The stock had a trading volume of 3,795,900 shares, compared to its average volume of 3,701,909. Eli Lilly and has a twelve month low of $72.68 and a twelve month high of $89.09. The stock has a market cap of $95,321.80, a P/E ratio of 21.17, a PEG ratio of 1.79 and a beta of 0.35. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03.

The company also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be paid a dividend of $0.5625 per share. This represents a $2.25 annualized dividend and a yield of 2.61%. The ex-dividend date of this dividend is Wednesday, February 14th. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s payout ratio is presently 98.58%.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 205,000 shares of the business’s stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $86.81, for a total transaction of $17,796,050.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Susan Mahony sold 36,585 shares of the business’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $86.18, for a total value of $3,152,895.30. Following the sale, the senior vice president now owns 54,885 shares in the company, valued at approximately $4,729,989.30. The disclosure for this sale can be found here. In the last quarter, insiders have sold 651,088 shares of company stock worth $56,439,586. Company insiders own 0.20% of the company’s stock.

Institutional investors have recently bought and sold shares of the business. BlackRock Inc. lifted its holdings in shares of Eli Lilly and by 2,628.5% in the 1st quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock valued at $5,236,731,000 after buying an additional 59,978,664 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Eli Lilly and by 7,093.5% in the 2nd quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock valued at $769,774,000 after buying an additional 9,223,251 shares during the period. Dodge & Cox lifted its holdings in shares of Eli Lilly and by 22,094.9% in the 2nd quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock valued at $493,138,000 after buying an additional 5,964,955 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Eli Lilly and by 91.1% in the 2nd quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock valued at $468,691,000 after buying an additional 2,714,505 shares during the period. Finally, Vanguard Group Inc. raised its holdings in Eli Lilly and by 3.3% in the 1st quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock worth $5,769,694,000 after purchasing an additional 2,181,701 shares during the period. Institutional investors and hedge funds own 76.30% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Eli Lilly and Company (LLY) Expected to Post Quarterly Sales of $5.96 Billion” was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/19/eli-lilly-and-company-lly-expected-to-post-quarterly-sales-of-5-96-billion.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Get a free copy of the Zacks research report on Eli Lilly and (LLY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.